BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32564819)

  • 1. Re: Goldberg et al.: A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease (Ophthalmology. 2019;126:1230-1237).
    Kanda M; Nowak V
    Ophthalmology; 2020 Jul; 127(7):e43. PubMed ID: 32564819
    [No Abstract]   [Full Text] [Related]  

  • 2. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
    Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
    Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
    Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
    Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new role for eye care practitioners in management of dry eye-with and without contact lenses.
    Chalmers RL; Guillon M
    Cont Lens Anterior Eye; 2010 Apr; 33(2):47-8. PubMed ID: 20227635
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
    Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
    Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
    Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
    Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
    Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
    Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena).
    Vogel R; Crockett RS; Oden N; Laliberte TW; Molina L;
    Am J Ophthalmol; 2010 Apr; 149(4):594-601. PubMed ID: 20346777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model.
    Petrov A; Perekhvatova N; Skulachev M; Stein L; Ousler G
    Adv Ther; 2016 Jan; 33(1):96-115. PubMed ID: 26733410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease.
    Yerxa BR; Mundasad M; Sylvester RN; Garden JC; Cooper M; Kellerman DJ
    Adv Exp Med Biol; 2002; 506(Pt B):1251-7. PubMed ID: 12614062
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of hypotonic and isotonic solutions containing sodium hyaluronate on the symptomatic treatment of dry eye patients.
    Papa V; Aragona P; Russo S; Di Bella A; Russo P; Milazzo G
    Ophthalmologica; 2001; 215(2):124-7. PubMed ID: 11244343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trehalose eye drops in the treatment of dry eye syndrome.
    Matsuo T; Tsuchida Y; Morimoto N
    Ophthalmology; 2002 Nov; 109(11):2024-9. PubMed ID: 12414409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
    Brzheskiy VV; Efimova EL; Vorontsova TN; Alekseev VN; Gusarevich OG; Shaidurova KN; Ryabtseva AA; Andryukhina OM; Kamenskikh TG; Sumarokova ES; Miljudin ES; Egorov EA; Lebedev OI; Surov AV; Korol AR; Nasinnyk IO; Bezditko PA; Muzhychuk OP; Vygodin VA; Yani EV; Savchenko AY; Karger EM; Fedorkin ON; Mironov AN; Ostapenko V; Popeko NA; Skulachev VP; Skulachev MV
    Adv Ther; 2015 Dec; 32(12):1263-79. PubMed ID: 26660938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
    Sosne G; Dunn SP; Kim C
    Cornea; 2015 May; 34(5):491-6. PubMed ID: 25826322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study.
    Moscovici BK; Holzchuh R; Sakassegawa-Naves FE; Hoshino-Ruiz DR; Albers MB; Santo RM; Hida RY
    Cont Lens Anterior Eye; 2015 Oct; 38(5):373-8. PubMed ID: 25956572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.